Rubio-San-Simón, A.
Hladun Alvaro, R.
Juan Ribelles, A.
Castañeda Heredia, A.
Guerra-García, P.
Verdú-Amorós, J.
Andrés, M.
Cañete, A.
Rives, S.
Pérez-Martínez, A.
Mora, J.
Patiño-García, A.
Lassaleta, A.
Llort, A.
Ramírez, M.
Mata, C.
Gallego, S.
Martín-Broto, J.
Cruz, O.
Morales La Madrid, A.
Solano, P.
Martínez Romera, I.
Fernández‑Teijeiro, A.
Bautista, F. http://orcid.org/0000-0002-0421-8862
Moreno, L.
Article History
Received: 8 May 2021
Accepted: 17 May 2021
First Online: 2 June 2021
Declarations
:
: R. Hladun had an advisory role for Roche, and she received honoraria from EusaPharma for an educational event. A. Cañete had a consulting or advisory role for EusaPharma and Bayer. She received honoraria from EusaPharma for educational events and travel expenses. A Cañete is a member of the Executive Committee of SIOPEN (European neuroblastoma research cooperative group) non-profit organization that receives royalties for the sales of dinutuximab beta. S Rives is a member of a data monitoring committee (DMC) and of de Study Steering Committee (SSC) for clinical trials sponsored by Novartis, had a consultant or advisory role for Novartis, Kite/Gilead, Juno/Bristol-Myers, Baxalta/Servier, Amgen, JazzPharma and received honoraria for speaking at symposia from Novartis, Servier, Amgen, Jazz Pharma. M. Ramírez receives grant money from Orgenesis. S. Gallego had advisory role and received personal fees from Bayer, Loxo Oncology, and EusaPharma. A. Fernández-Teijeiro had a consulting or advisory role for Amgen, Novartis, Takeda, Bayer, Roche, and Sobi. She received honoraria from Takeda, Amgen, Novartis and Sobi for educational events and travel expenses from Servier, Shire, Takeda and Gilead. L. Moreno is member of data monitoring committees for clinical trials sponsored by Novartis, Actuate Therapeutics, Shionogi, Incyte, the University of Southampton and the Royal Marsden NHS Foundation Trust; and had a consulting role for Novartis and Shionogi. Dr. Lucas Moreno is member of the Executive Committee of SIOPEN which receives royalties for the sales of dinutuximab beta. His institution receives funding from sponsors for DMC participation, advisory role or conducting industry-sponsored clinical trials. F. Bautista is a member of a DMC for a clinical trial sponsored by Sanofi, had a consultant or advisory role for Bayer, Amgen, Roche Genentech and EusaPharma and received honoraria for speaking at symposia from Roche Genentech. The rest of the authors declare that they have no conflicts of interest.
: The study does not involved human participants, their data or biological material so, according to Spanish national law.
: Not needed for this study.
: Not needed for this study.